Connect with us

Business

REIT Replay: Office REIT Stocks Plummet In Recent Week Amid Growing AI Fears

Published

on

REIT Replay: Office REIT Stocks Plummet In Recent Week Amid Growing AI Fears
Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Business

Dutch Bros delivers ‘record-breaking year’

Published

on

Dutch Bros delivers ‘record-breaking year’

Income surges 126% to nearly $80 million.

Continue Reading

Business

Mamdani pushes for New York tax hike on the wealthy and corporations

Published

on

Mamdani pushes for New York tax hike on the wealthy and corporations

New York City Mayor Zohran Mamdani is calling for the Empire State to hike taxes on corporations and wealthy individuals in order to address the Big Apple’s budget deficit, warning that the alternative would involve the city increasing property taxes and dipping into its reserves.

Mamdani has issued a preliminary fiscal year 2027 budget that involves a property tax hike, a prospect he has described as a “last resort.”

Advertisement

“Today, I’m releasing the City’s preliminary budget. After years of fiscal mismanagement, we’re staring at a $5.4 billion budget gap — and two paths. One: Albany can raise taxes on the ultra-wealthy and the most profitable corporations and address the fiscal imbalance between our city and state. The other, a last resort: balance the budget on the backs of working people using the only tools at the City’s disposal,” Mamdani noted in a Tuesday post on X.

FREE BUSES, REAL COSTS. INSIDE MAMDANI’S SOCIALIST DREAM TO SHAKEUP TRANSIT FOR NEW YORKERS

New York City Mayor Zohran Mamdani

New York City Mayor Zohran Mamdani during a Bloomberg Television interview at City Hall in New York, on Thursday, Jan. 29, 2026.  (Michael Nagle/Bloomberg via Getty Images / Getty Images)

The city council needs to green-light city budgets, according to the New York Times.

“As the mayor of New York City, I have a legal obligation to balance the budget. I will meet that obligation,” he said during remarks on Tuesday.

Advertisement

MICHAEL RAPAPORT BLASTS NYC AS ‘DIRTY SNOW COVERED DUMP’ AS CELEBS CALL OUT MAYOR MAMDANI OVER SLOW CLEANUP

New York City

The sun sets on the Statue of Liberty and the Empire State Building in New York City on July 28, 2025, as seen from Bayonne, N.J. (Gary Hershorn/Getty Images / Getty Images)

“Faced with no other choice, the city would have to exercise the only revenue lever fully within our own control. We would have to raise property taxes. We would also be forced to raid our reserves,” he said. 

“This would effectively be a tax on working and middle class New Yorkers, who have a median income of $122,000,” said Mamdani, a self-described Democratic socialist who ran on a platform that promised to tackle rent costs.

HOUSE GOP LEADER RIPS ‘SOCIALIST’ ZOHRAN MAMDANI AFTER 18 PEOPLE FREEZE TO DEATH IN NYC

Advertisement
New York City Mayor Zohran Mamdani

New York City Mayor Zohran Mamdani during an announcement on junk fees in the Susan and John Hess Family Theater at The Whitney Museum of American Art in New York, on Wednesday, Jan. 21, 2026. (Adam Gray/Bloomberg via Getty Images / Getty Images)

GET FOX BUSINESS ON THE GO BY CLICKING HERE

Mamdani said the “preliminary budget takes the only path within our control,” but added that the city will only go that route if there is no other way to achieve a balanced budget.

Continue Reading

Business

Bank of Hawaii stock hits 52-week high at 80.25 USD

Published

on


Bank of Hawaii stock hits 52-week high at 80.25 USD

Continue Reading

Business

Defence giant BAE hails record sales as workers remain on strike

Published

on

Defence giant BAE hails record sales as workers remain on strike

Speaking after the company’s record results, Woodburn, who has run BAE since 2017, said: “In a new era of defence spending, driven by escalating security challenges, we’re well-positioned to provide both the advanced conventional systems and disruptive technologies needed to protect the nations we serve now and into the future.”

Continue Reading

Business

Lagarde’s possible early departure leaves investors pondering replacements

Published

on

Lagarde’s possible early departure leaves investors pondering replacements


Lagarde’s possible early departure leaves investors pondering replacements

Continue Reading

Business

Upstart’s Technology Has Taken The Next Step (Rating Upgrade) (NASDAQ:UPST)

Published

on

Upstart's Technology Has Taken The Next Step (Rating Upgrade) (NASDAQ:UPST)

This article was written by

I am an individual investor, working at a global technology company. I have an academic background in engineering and business economics and am currently pursuing a PhD in economics. I started investing while attending university in 2012 and have a focus in technology-based growth stocks, particularly in the fields of renewable energy, hydrogen, new mobility and space. As I aim to identify growth stocks for a diversified portfolio early on, the companies I invest in are usually small or micro caps which are not covered by a lot of analysts and SA contributors. I will thus share my thoughts from time to time with articles if I feel there are interesting yet under-evaluated investment ideas to contribute. My investment style is long only and I invest to hold for the long-term. In my analyses, I focus on fundamental topics such as technology, business model and valuation relative to the addressed market.

Analyst’s Disclosure: I/we have a beneficial long position in the shares of UPST, PGY either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Advertisement
Continue Reading

Business

General Mills reduces forecast for fiscal 2026

Published

on

General Mills reduces forecast for fiscal 2026

“Challenging consumer environment” cited for guidance adjustment.

Continue Reading

Business

More drugs should be over-the-counter

Published

on

More drugs should be over-the-counter
FDA's Marty Makary: Everything should be over-the-counter unless it's unsafe or requires monitoring

Food and Drug Administration Commissioner Marty Makary told CNBC that he believes “everything should be over-the-counter” unless a drug is unsafe, addictive or requires monitoring – doubling down on a push that some in the pharmaceutical industry have questioned

In an interview on Wednesday in Washington, D.C., Makary said the FDA’s aims to make changes this year that allow more companies to make their prescription medicines available over-the-counter, or OTC. He noted that the agency is going through “the proper regulatory processes” to update OTC monographs –  the rulebooks that determine which drugs can be sold without a prescription. 

Makary said the FDA is looking at “basic, safe” prescription drugs like nausea medications and vaginal estrogen, which is used to treat menopausal symptoms like dryness and pain. 

“In my opinion, everything should be over-the-counter and not requiring a prescription, unless it’s unsafe, unless you need laboratory test to monitor how it’s being received by your body, or if it could be used for some nefarious purpose or it’s addictive,” Makary told CNBC after the PhRMA Forum, a one-day event organized by the pharmaceutical industry’s largest lobbying group. 

Advertisement

“If it doesn’t meet those criteria, why shouldn’t a drug be over the counter? So we should be asking, why not? Instead of, ‘Oh, you want to move over the counter, you got to go through a long, tedious process,’” he added. 

Marty Makary, U.S. President Donald Trump’s nominee to be U.S. Food and Drug Administration (FDA) commissioner, testifies before a Health, Education, Labor, and Pensions (HELP) Senate Committee confirmation hearing on Capitol Hill in Washington, D.C., U.S., March 6, 2025. 

Kent Nishimura | Reuters

The FDA has long considered making some prescription drugs available OTC to improve accessibility, reduce health-care costs and help patients stay on their medications. For example, patients wouldn’t have to take time off work to see a doctor for a prescription or could refill a drug without delay.

Advertisement

Congress boosted the effort through legislation in November that streamlines the regulatory process for prescription-to-OTC transitions, including full, conditional and partial “switch” pathways.

Makary framed the FDA’s latest push to expand OTC access as another way to lower drug costs, a key priority of the Trump administration. He argued that placing medications directly on store shelves would bypass insurers and pharmacy benefit managers, eliminating the rebate-driven system that often obscures a drug’s true price.

He also said selling drugs over the counter promotes transparency that “keeps prices in check.” In some cases, Makary said cash prices for OTC medicines are lower than patients’ copays for prescription drugs “when there’s a money game going on behind the pharmacy counter,” with employers and insurers sharing the cost.

Pharma questions OTC push

Some in the pharmaceutical industry have pushed back on that argument. Most OTC drugs are not covered by insurance, meaning their prices could eclipse those of generic prescription medicines and potentially make them less affordable for patients who rely on coverage. 

Advertisement

In comments to the FDA earlier this month, the Association for Accessible Medicines argued that “the shift of many prescription drugs to nonprescription status could actually increase costs to patients, thereby decreasing patient access to treatments.” That organization represents manufacturers and distributors of generic prescription medicines. 

The FDA also doesn’t have the authority to regulate drug prices. In its own comments this month, PhRMA said the agency must respect “the core principle that pricing considerations may not factor into FDA regulatory decision-making.”

PhRMA added that the FDA should not attempt to transition any prescription drugs to OTC without first consulting manufacturers. But the group emphasized that it supports the FDA’s effort to expand access to crucial medicines. 

In its own comment this month, AstraZeneca said several previous attempts to transition cholesterol-cutting statins to OTC status have been “unsuccessful, with consumers consistently having difficulty making proper self-selection decisions.” 

Advertisement

Meanwhile, Makary told CNBC on Wednesday that “we have to trust people to make their decisions. We’ve got to get away from this paternalistic mindset.”

The FDA removed the longtime director of the office of over-the-counter drugs, Theresa Michele, from her position in December, STAT news reported at the time. 

Continue Reading

Business

Mondelez CEO on the five things that worry him

Published

on

Mondelez CEO on the five things that worry him

Consumer sentiment and ultra-processed foods top the list. 

Continue Reading

Business

More than 150 jobs lost as East Yorkshire maker collapses into administration

Published

on

Business Live

Administrators confirm the Goole-based emergency vehicle manufacturer has shut down after more than 30 years

O&H Vehicle Conversions has filed a notice of intention to appoint administrators

O&H Vehicle Conversions had filed a notice of intention to appoint administrators(Image: O&H Vehicle Conversions)

Hopes that jobs could be saved at a Goole-based manufacturer of emergency vehicles have been dashed after administrators were officially appointed. Insolvency experts were brought in to O&H Vehicle Conversions last week amid financial difficulties.

The development brings to an end more than three decades of production at the firm’s Larsen Road facility, and results in the loss of 157 positions. Administrators from BDO LLP said the business had been affected by delivery delays which impacted revenue and cashflow, with the directors believed to be left with no alternative but to place the company into administration.

Attempts to market the business had been ongoing even before BDO’s appointment but a sale as a solvent, going concern could not be achieved. O&H’s 64,000 sqft plant which manufactured ambulances and other rapid response emergency vehicles is now shut.

Mark Thornton, one of the joint administrators said: “It is always a sad day when a longstanding business is forced to close. Given the financial position and outlook for the company, securing a sale of the business as a going concern was not possible.

Advertisement

“The priority of the joint administrators will now be to support employees impacted by the closure and realise assets in line with our duties in order to maximise the return for creditors.”, reports Hull Live.

The shuttering of O&H comes just weeks after CEO Mark Brickhill released a statement saying that since November of the previous year, approximately £2.2m in sales had been postponed. He stated that O&H had received support from shareholders for years, amounting to over £25m in a “very challenging industry”.

The most recent accounts for O&H Vehicle Conversions Group Ltd, spanning the year up to the end of February 2024, reveal a turnover of £22.3m and operating losses exceeding £9.7m. In those accounts, executives attributed delays to multi-year NHS Trust orders for ambulances which needed new post-Brexit accreditations.

Several O&H employees have taken to social media in recent days in search of new employment opportunities. A former director said: “It’s a difficult day, saying goodbye to so many talented and dedicated colleagues at O&H. People who showed up every day with pride, resilience, and a genuine commitment to doing things the right way. Watching a team like that be broken apart is heart breaking.

Advertisement

“I’m incredibly proud of what we achieved together, and I’m grateful for the friendships, the support, and the professionalism you all brought to work every single day. To everyone affected, I wish you nothing but success in finding your next role and hope our paths cross again. If anyone reading this can help my colleagues into their next opportunity, please do reach out to them.”

Continue Reading

Trending

Copyright © 2025